Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04575519
Other study ID # SMA-TB-001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 4, 2021
Est. completion date June 2025

Study information

Verified date March 2024
Source Fundació Institut Germans Trias i Pujol
Contact Cristina Vilaplana, MD, PhD
Phone +34930330527
Email cvilaplana@igtp.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of 2 repurposed drugs (acetylsalicylic acid and ibuprofen), for use as adjunct therapy added to, and compared with, the standard of care (SoC) WHO-recommended TB regimen in drug-sensitive (DS) and multi-drug resistant (MDR) TB patients.


Description:

If eligible and informed consent obtained, patients will be randomized 1:1:1 into one of the following 3 arms, to receive: 1. Standard of Care (SoC) TB treatment + placebo twice daily during the first 4 weeks of TB treatment followed by placebo once daily for an additional 4 weeks. (control group). 2. SoC TB treatment + acetylsalicylic acid 300mg twice daily during the first 4 weeks of TB treatment followed by acetylsalicylic acid 300mg once daily for an additional 4 weeks. 3. SoC TB treatment + ibuprofen 400mg twice daily during the first 4 weeks of TB treatment followed by ibuprofen 400mg once daily for an additional 4 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 354
Est. completion date June 2025
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Adults, 18- 60 years of age 2. Written informed consent in a language they understand. This includes informed consent to be in the trial and informed consent to collect specimens. 3. Laboratory confirmed pulmonary TB (with or without extrapulmonary involvement) defined as a hard copy of a sputum laboratory result that reports M. tuberculosis (Mtb) detection by a WHO-recommended assay -both rapid molecular assays or mycobacterial culture with subsequent speciation are acceptable as inclusion criteria. 4. Women of childbearing potential (including females <2 years post-menopausal) must have a negative pregnancy test at enrolment. 5. Participants must be willing to have an HIV test done unless there is compelling evidence that the patient is HIV-infected at the time of randomization. Exclusion Criteria: 1. Has a comorbid condition where treatment with aspirin, ibuprofen or other NSAID is indicated (e.g. cardiovascular disease, rheumatic fever, chronic pain, etc.) 2. People institutionalized (incarceration in jail or prison, or due to chronic mental illness). If incarcerated during the study, participants may be terminated, those incarcerated in the first 8 weeks of follow up will be late exclusions and replaced*. Patients either who are planned to be hospitalized or currently hospitalized whilst treated for MDR TB in a TB hospital or ward may be enrolled. 3. Receipt of multi-drug TB treatment (including rifamycin plus isoniazid preventive treatment regimens) for =3 days in the 6 months prior to randomization. Participants who have received =3 days of TB preventive treatment in the month prior to TB treatment initiation will also be excluded. 4. Currently Pregnancy/breastfeeding. Women who conceive and are found to be pregnant in the first 4 weeks of the trial will be terminated from the trial and excluded from the analysis. 5. Any of the following laboratory parameters taken prior to randomization: - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN); - Total bilirubin > 2 x ULN; - Neutrophil count = 700 neutrophils /mm3; - Platelet count < 50,000 cells / mm3 - Haemoglobin concentration less than 8 g/dL - Serum creatinine concentration more than twice the upper limit of normal 6. Co-treatment in the three months prior to randomization, or planned treatment over the course of the trial follow up with any one of the following agents: - anticoagulant therapy - immune modulating therapy (cancer treatments, any oral or daily use of inhaled steroids; - Antacids or proton pump inhibitors - including self-treatment and prescription 7. History or clinical record of sensitivity, asthma or allergy that could be attributed to NSAIDs 8. Weight < 45kg at baseline. 9. History or clinical record suggestive of any of the following in the past two years: - peptic ulcer disease or gastro-intestinal bleeding, - coagulopathy or other bleeding disorder, - renal disease requiring hospitalization - in addition, any prior record at any time of acute kidney injury will be an exclusion criterion. - liver disease requiring further investigation or hospitalization, - underlying cardiovascular disease or risk factors for cardiovascular disease. 10. Patients with HIV infection (irrespective of ART status) if: - CD4 <350 cells/mm3 - if on ART, unsuppressed (>200 copies/ml) viral load - if not on ART, either in the opinion of the attending doctor or according to local ART guidelines, the patient should initiate ART during the 8-week initial placebo or NSAID treatment phase. 11. Alcohol use: potential participant either self-reports or in the investigator's opinion that the patient drinks more than an average of four units/day over a usual week or is a binge drinker (men: 5 or more drinks; women: consume 4 or more drinks, in about 2 hours). 12. Major co-morbid conditions or any other finding which in the opinion of the investigator would compromise the protocol compliance or significantly influence the interpretation of results.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Control group
placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
ASA group
Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
IBU group
Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
SoC TB
Standard of Care Tuberculosis treatment

Locations

Country Name City State
Georgia National Center for Tuberculosis and Lung Diseases Tbilisi
South Africa PHRU- Matlosana, Tshepong Hospital MDR Unit Klerksdorp Matlosana
South Africa Perinatal HIV Unit (PHRU)- Chris Hani Baragwanath Hospital Soweto Johannesburg

Sponsors (3)

Lead Sponsor Collaborator
Fundació Institut Germans Trias i Pujol National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia, Perinatal HIV Research Unit of the University of the Witswatersrand

Countries where clinical trial is conducted

Georgia,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety 1: SAEs participant proportion. Proportion of participants with at least one serious adverse events (SAEs) by arm until the end of TB treatment, between each intervention arm and the control group. Up to month 6 in DS TB patients and up to month 20 in MDR TB patients
Other Safety 2: SAEs in person time. Serious adverse event (SAEs) rate expressed in person time, starting the day of the first dose of NSAID or placebo until one month (30 days) after the last placebo or NSAID taken, including all adverse events recorded in each arm. Up to week 12
Other Tolerability 1: permanent discontinuity proportion. The proportion of patients in each arm who either permanently discontinued either placebo, acetylsalicylic acid or ibuprofen. Up to week 8
Other Tolerability 2: treatment interruption proportion The proportion of patients in each arm who had TB treatment interruption for longer than seven days/doses, prescribed either by a listed investigator, or a non-study physician up to two weeks after scheduled or unscheduled permanent discontinuation of placebo/NSAID Up to week 10
Primary Time to = 67% sustained reduction in the TB score Time to = 67% sustained reduction in the TB score over the course of TB treatment Week 8 of follow-up
Primary Hazard ratio for time to stable culture conversion (SCC) Hazard ratio for time to stable culture conversion (SCC), at least 2 consecutive negative cultures for M. tuberculosis at least 4 weeks apart during the first 24 weeks of TB treatment. 24 weeks of TB treatment
Secondary Hazard ratio for stable culture conversion (SCC) at week 8 and week 16 after treatment start. Difference between each intervention arm and control group At week 8 and week 16
Secondary Proportion of patients with improvement or resolution of clinical signs and symptoms at end of treatment (TB score). Difference between each intervention arm and control group At week 24
Secondary Proportion of patients with improvement of lung function impairment as change from baseline at week 8, 24 and end of treatment in the 1-second forced expiratory volume (FEV1) expressed as FEV1. Difference between each intervention arm and control group At baseline, week 8 and week 24
Secondary Changes in the BCN-SA Radiological Score Value. Change in chest-X ray (measured with the BCN-SA score) using the x-ray taken at baseline as the comparator compared with subsequent x-rays over the course of TB therapy. Difference between each intervention arm and control group. The BCN-SA Radiological Score Value assesses the sum of acute and chronic findings in the chest X-ray. Per each finding, a minimum score of 0 and a maximum score of 8 is recorded. The total score value is calculated by adding all the individual findings score values. Higher values of total score represent a worse outcome. At baseline, week 8, week 24 (and month 12 if MDR)
Secondary Number of patients with improvement of Health-related Quality of Life comparing baseline measure with that over the course of therapy. Difference between each intervention arm and control group At week 8, week 24 and for MDR TB patients at the end of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06084715 - The INSTITUT Study
Terminated NCT03028129 - Prevention of Tuberculosis in Prisons Phase 4
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Withdrawn NCT03862248 - Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More Phase 3
Completed NCT03271567 - Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Active, not recruiting NCT04919239 - Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) Phase 2
Active, not recruiting NCT03251196 - TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
Recruiting NCT05926466 - BTZ-043 Dose Evaluation in Combination and Selection Phase 2
Recruiting NCT04752592 - Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Not yet recruiting NCT04968886 - TuBerculosis Viability Interregional Study and Agreement on Biological Tests
Not yet recruiting NCT04485156 - Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) Phase 3
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT01364324 - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Active, not recruiting NCT04179500 - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers Phase 2
Completed NCT05899400 - A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
Completed NCT04938596 - Airborne Preventive Measures to Reduce New TB Infections in Household Contacts N/A
Recruiting NCT05455112 - Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis Phase 2
Completed NCT03044158 - GeneXpert Performance Evaluation for Linkage to Tuberculosis Care N/A